Travere Therapeutics (TVTX) Competitors $14.91 +0.08 (+0.54%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$14.20 -0.71 (-4.76%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVTX vs. BPMC, SRPT, TLX, AXSM, KRYS, NUVL, GRFS, ELAN, VRNA, and ADMAShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Axsome Therapeutics (AXSM), Krystal Biotech (KRYS), Nuvalent (NUVL), Grifols (GRFS), Elanco Animal Health (ELAN), Verona Pharma (VRNA), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Travere Therapeutics vs. Blueprint Medicines Sarepta Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Axsome Therapeutics Krystal Biotech Nuvalent Grifols Elanco Animal Health Verona Pharma ADMA Biologics Travere Therapeutics (NASDAQ:TVTX) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends. Does the media prefer TVTX or BPMC? In the previous week, Travere Therapeutics had 5 more articles in the media than Blueprint Medicines. MarketBeat recorded 15 mentions for Travere Therapeutics and 10 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 1.03 beat Travere Therapeutics' score of 0.97 indicating that Blueprint Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Blueprint Medicines 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Does the MarketBeat Community prefer TVTX or BPMC? Blueprint Medicines received 460 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 68.15% of users gave Blueprint Medicines an outperform vote while only 60.81% of users gave Travere Therapeutics an outperform vote. CompanyUnderperformOutperformTravere TherapeuticsOutperform Votes9060.81% Underperform Votes5839.19% Blueprint MedicinesOutperform Votes55068.15% Underperform Votes25731.85% Which has more risk and volatility, TVTX or BPMC? Travere Therapeutics has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Do analysts rate TVTX or BPMC? Travere Therapeutics presently has a consensus price target of $32.08, suggesting a potential upside of 115.14%. Blueprint Medicines has a consensus price target of $124.95, suggesting a potential upside of 53.41%. Given Travere Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Travere Therapeutics is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Travere Therapeutics 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93Blueprint Medicines 1 Sell rating(s) 6 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 2.70 Which has higher valuation & earnings, TVTX or BPMC? Blueprint Medicines has higher revenue and earnings than Travere Therapeutics. Blueprint Medicines is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTravere Therapeutics$233.18M5.68-$111.40M-$4.10-3.64Blueprint Medicines$508.82M10.23-$67.09M-$1.08-75.42 Is TVTX or BPMC more profitable? Blueprint Medicines has a net margin of -13.19% compared to Travere Therapeutics' net margin of -137.90%. Blueprint Medicines' return on equity of -77.49% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Travere Therapeutics-137.90% -1,636.87% -55.95% Blueprint Medicines -13.19%-77.49%-20.84% SummaryBlueprint Medicines beats Travere Therapeutics on 12 of the 17 factors compared between the two stocks. Remove Ads Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVTX vs. The Competition Export to ExcelMetricTravere TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.32B$6.33B$5.33B$7.57BDividend YieldN/A3.23%5.11%4.33%P/E Ratio-3.646.8221.8317.81Price / Sales5.68225.92379.4694.58Price / CashN/A65.6738.1534.64Price / Book5.585.866.454.00Net Income-$111.40M$141.86M$3.20B$247.23M7 Day Performance5.37%9.22%6.60%7.26%1 Month Performance-24.43%-12.42%-8.50%-6.26%1 Year Performance135.92%-11.93%10.33%-0.18% Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVTXTravere Therapeutics2.5531 of 5 stars$14.91+0.5%$32.08+115.1%+135.9%$1.32B$233.18M-3.64460Analyst ForecastBPMCBlueprint Medicines2.6341 of 5 stars$80.20-1.8%$124.95+55.8%-4.4%$5.13B$508.82M-74.26640Positive NewsHigh Trading VolumeSRPTSarepta Therapeutics4.6781 of 5 stars$52.40-3.7%$163.18+211.4%-54.0%$5.08B$1.90B41.92840Short Interest ↑Gap DownHigh Trading VolumeTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$14.25+4.7%$22.00+54.4%N/A$4.81B$783.21M0.00N/AAXSMAxsome Therapeutics4.5817 of 5 stars$98.50-0.4%$169.80+72.4%+52.2%$4.80B$385.69M-16.44380Analyst RevisionKRYSKrystal Biotech4.6447 of 5 stars$166.01-3.1%$220.00+32.5%-0.4%$4.78B$290.52M55.52210NUVLNuvalent1.8517 of 5 stars$64.68-1.6%$113.44+75.4%+8.4%$4.63BN/A-18.6440Positive NewsGRFSGrifols3.0933 of 5 stars$6.55-1.5%N/A+6.9%$4.50B$7.21B5.6026,300Gap UpELANElanco Animal Health4.3455 of 5 stars$8.95-2.2%$15.17+69.6%-40.6%$4.44B$4.44B22.369,800Analyst ForecastGap DownVRNAVerona Pharma2.2461 of 5 stars$54.30+0.7%$69.14+27.3%+270.1%$4.39B$42.28M-28.2830Positive NewsGap UpHigh Trading VolumeADMAADMA Biologics1.8854 of 5 stars$18.40+2.2%$22.50+22.3%+270.4%$4.35B$426.45M65.71530Options VolumeNews CoveragePositive NewsGap Up Remove Ads Related Companies and Tools Related Companies Blueprint Medicines Competitors Sarepta Therapeutics Competitors Telix Pharmaceuticals Limited American Depositary Shares Competitors Axsome Therapeutics Competitors Krystal Biotech Competitors Nuvalent Competitors Grifols Competitors Elanco Animal Health Competitors Verona Pharma Competitors ADMA Biologics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVTX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TVTX Stock Free TVTX Stock Alerts